Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase NA × Oligometastatic Lung Adenocarcinoma × Erlotinib Hydrochloride × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 5 Oligometastatic Lung Adenocarcinoma 1 Neoplasms 1 Neoplasm Metastasis 1 NSCLC 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Gastrointestinal Neoplasms 1 EGFR Mutation Positive Non-small Cell Lung Cancer 1 Carcinoma 1 Breast Neoplasms 1

Interventions

Erlotinib Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02450591 2018-05-21

Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Memorial Sloan Kettering Cancer Center

Phase NA Completed

4 enrolled 7 charts

Oligometastatic Lung Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡